Minimal residual disease evaluation in acute myeloid leukaemia (Q34749454)

4 August 2017

1 reference

title

Minimal residual disease evaluation in acute myeloid leukaemia (English)

1 reference

4 August 2017

1 reference

John A Liu Yin

1

1 reference

4 August 2017

David Grimwade

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

360

1 reference

4 August 2017

issue

9327

1 reference

4 August 2017

page(s)

160-162

1 reference

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

The significance of minimal residual disease in patients with t(15;17).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Minimal residual disease in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Screening for core binding factor gene rearrangements in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909419-9

7 January 2021

10.1016/S0140-6736(02)09419-9

Identifiers

DOI

1 reference

4 August 2017

1 reference